{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T05:07:59Z","timestamp":1764997679860,"version":"3.41.2"},"reference-count":33,"publisher":"Pharmaceutical Society of Japan","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,7,30]]},"DOI":"10.1248\/bpb.b25-00249","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T22:08:11Z","timestamp":1753826891000},"page":"1118-1124","source":"Crossref","is-referenced-by-count":1,"title":["Suppressive Effects of JTE-151, a Novel Orally Available ROR&lt;i&gt;\u03b3&lt;\/i&gt; Antagonist, in Experimental Models of Rheumatoid Arthritis"],"prefix":"10.1248","volume":"48","author":[{"given":"Kojo","family":"Arita","sequence":"first","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1\u20131 Murasaki-cho, Takatsuki, Osaka 569\u20131125, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Otake","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1\u20131 Murasaki-cho, Takatsuki, Osaka 569\u20131125, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1\u20131 Murasaki-cho, Takatsuki, Osaka 569\u20131125, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1\u20131 Murasaki-cho, Takatsuki, Osaka 569\u20131125, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1\u20131 Murasaki-cho, Takatsuki, Osaka 569\u20131125, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Katsuda","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1\u20131 Murasaki-cho, Takatsuki, Osaka 569\u20131125, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Konishi","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1\u20131 Murasaki-cho, Takatsuki, Osaka 569\u20131125, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1\u20131 Murasaki-cho, Takatsuki, Osaka 569\u20131125, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Almutairi KB, Nossent JC, Preen DB, Keen HI, Inderjeeth CA. The prevalence of rheumatoid arthritis: a systematic review of population-based studies. <i>J. Rheumatol.<\/i>, <b>48<\/b>, 669\u2013676 (2021).","DOI":"10.3899\/jrheum.200367"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Lin YJ, Anzaghe M, Sch\u00fclke S. Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis. <i>Cells<\/i>, <b>9<\/b>, 880 (2020).","DOI":"10.3390\/cells9040880"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Safiri S, Kolahi AA, Hoy D, Smith E, Bettampadi D, Mansournia MA, Almasi-Hashiani A, Ashrafi-Asgarabad A, Moradi-Lakeh M, Qorbani M, Collins G, Woolf AD, March L, Cross M. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017. <i>Ann. Rheum. Dis.<\/i>, <b>78<\/b>, 1463\u20131471 (2019).","DOI":"10.1136\/annrheumdis-2019-215920"},{"key":"4","unstructured":"4) Fraenkel L, Bathon JM, England BR, <i>et al<\/i>. American College of Rheumatology guideline for the treatment of rheumatoid arthritis. <i>Arthritis Rheumatol.<\/i>, <b>73<\/b>, 1108\u20131123 (2021)."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Smolen JS, Landew\u00e9 RBM, Bergstra SA, <i>et al<\/i>. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. <i>Ann. Rheum. Dis.<\/i>, <b>82<\/b>, 3\u201318 (2023).","DOI":"10.1136\/ard-2022-223356corr1"},{"key":"6","unstructured":"6) Nagy G, Roodenrijs NMT, Welsing PM, <i>et al<\/i>. EULAR definition of difficult-to-treat rheumatoid arthritis. <i>Ann. Rheum. Dis.<\/i>, <b>80<\/b>, 31\u201335 (2021)."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Takanashi S, Kaneko Y. Unmet needs and current challenges of rheumatoid arthritis: difficult-to-treat rheumatoid arthritis and late-onset rheumatoid arthritis. <i>J. Clin. Med.<\/i>, <b>13<\/b>, 7594 (2024).","DOI":"10.3390\/jcm13247594"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Mori S, Hidaka M, Kawakita T, Hidaka T, Tsuda H, Yoshitama T, Migita K, Ueki Y. Factors associated with myelosuppression related to low-dose methotrexate therapy for inflammatory rheumatic diseases. <i>PLOS ONE<\/i>, <b>11<\/b>, e0154744 (2016).","DOI":"10.1371\/journal.pone.0154744"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. <i>JAMA<\/i>, <b>295<\/b>, 2275\u20132285 (2006).","DOI":"10.1001\/jama.295.19.2275"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Harrington R, Al Nokhatha SA, Conway R. JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data. <i>J. Inflamm. Res.<\/i>, <b>13<\/b>, 519\u2013531 (2020).","DOI":"10.2147\/JIR.S219586"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Hresko A, Lin TC, Solomon DH. Medical care costs associated with rheumatoid arthritis in the US: a systematic literature review and meta-analysis. <i>Arthritis Care Res. (Hoboken)<\/i>, <b>70<\/b>, 1431\u20131438 (2018).","DOI":"10.1002\/acr.23512"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Weyand CM, Goronzy JJ. The immunology of rheumatoid arthritis. <i>Nat. Immunol.<\/i>, <b>22<\/b>, 10\u201318 (2021).","DOI":"10.1038\/s41590-020-00816-x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) van Hamburg JP, Tas SW. Molecular mechanisms underpinning T helper 17 cell heterogeneity and functions in rheumatoid arthritis. <i>J. Autoimmun.<\/i>, <b>87<\/b>, 69\u201381 (2018).","DOI":"10.1016\/j.jaut.2017.12.006"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Leipe J, Grunke M, Dechant C, Reindl C, Kerzendorf U, Schulze-Koops H, Skapenko A. Role of Th17 cells in human autoimmune arthritis. <i>Arthritis Rheum.<\/i>, <b>62<\/b>, 2876\u20132885 (2010).","DOI":"10.1002\/art.27622"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Shen H, Goodall JC, Hill Gaston JS. Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis. <i>Arthritis Rheum<\/i>., <b>60<\/b>, 1647\u20131656 (2009).","DOI":"10.1002\/art.24568"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Lubberts E. The IL-23-IL-17 axis in inflammatory arthritis. <i>Nat. Rev. Rheumatol.<\/i>, <b>11<\/b>, 415\u2013429 (2015).","DOI":"10.1038\/nrrheum.2015.53"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR. The orphan nuclear receptor ROR\u03b3t directs the differentiation program of proinflammatory IL-17<sup>+<\/sup> T helper cells. <i>Cell<\/i>, <b>126<\/b>, 1121\u20131133 (2006).","DOI":"10.1016\/j.cell.2006.07.035"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Arita K, Tao H, Crowe P, Thacher S, Otake S, Kobayashi K, Ebihara S, Okamoto Y, Katsuda Y, Yamaguchi T, Matsushita M. Pharmacological properties of JTE-151; a novel orally available ROR<i>\u03b3<\/i> antagonist that suppress Th17 cell-related responses <i>in vitro<\/i> and <i>in vivo<\/i>. <i>Biol. Pharm. Bull.<\/i>, <b>47<\/b>, 2050\u20132057 (2024).","DOI":"10.1248\/bpb.b24-00490"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Tanimoto A, Ogawa Y, Oki C, Kimoto Y, Nozawa K, Amano W, Noji S, Shiozaki M, Matsuo A, Shinozaki Y, Matsushita M. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses <i>in vitro<\/i> and <i>in vivo<\/i>. <i>Inflamm. Res.<\/i>, <b>64<\/b>, 41\u201351 (2015).","DOI":"10.1007\/s00011-014-0782-9"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Uesato N, Kitagawa Y, Matsuo Y, Miyagawa N, Inagaki K, Kakefuda R, Yamaguchi T, Hata T, Ikegashira K, Matsushita M. Therapeutic effect of colony stimulating factor 1 receptor kinase inhibitor, JTE-952, on methotrexate-refractory pathology in a rat model of rheumatoid arthritis. <i>Biol. Pharm. Bull.<\/i>, <b>46<\/b>, 1223\u20131230 (2023).","DOI":"10.1248\/bpb.b23-00148"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Wang S, Zhou Y, Huang J, Li H, Pang H, Niu D, Li G, Wang F, Zhou Z, Liu Z. Advances in experimental models of rheumatoid arthritis. <i>Eur. J. Immunol.<\/i>, <b>53<\/b>, 2249962 (2023).","DOI":"10.1002\/eji.202249962"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Dekkers JS, Schoones JW, Huizinga TW, Toes RE, van der Helm-van Mil AH. Possibilities for preventive treatment in rheumatoid arthritis? Lessons from experimental animal models of arthritis: a systematic literature review and meta-analysis. <i>Ann. Rheum. Dis.<\/i>, <b>76<\/b>, 458\u2013467 (2017).","DOI":"10.1136\/annrheumdis-2016-209830"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Aur\u00e9al M, Machuca-Gayet I, Coury F. Rheumatoid arthritis in the view of osteoimmunology. <i>Biomolecules<\/i>, <b>11<\/b>, 48 (2020).","DOI":"10.3390\/biom11010048"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Kim KW, Kim HR, Kim BM, Cho ML, Lee SH. Th17 cytokines regulate osteoclastogenesis in rheumatoid arthritis. <i>Am. J. Pathol.<\/i>, <b>185<\/b>, 3011\u20133024 (2015).","DOI":"10.1016\/j.ajpath.2015.07.017"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Tuncer T, Kaya A, Gulkesen A, Kal GA, Kaman D, Akgol G. Matrix metalloproteinase-3 levels in relation to disease activity and radiological progression in rheumatoid arthritis. <i>Adv. Clin. Exp. Med.<\/i>, <b>28<\/b>, 665\u2013670 (2019).","DOI":"10.17219\/acem\/94065"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Venkatesha SH, Dudics S, Weingartner E, So EC, Pedra J, Moudgil KD. Altered Th17\/Treg balance and dysregulated IL-1\u03b2 response influence susceptibility\/resistance to experimental autoimmune arthritis. <i>Int. J. Immunopathol. Pharmacol.<\/i>, <b>28<\/b>, 318\u2013328 (2015).","DOI":"10.1177\/0394632015595757"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Stolina M, Bolon B, Middleton S, Dwyer D, Brown H, Duryea D, Zhu L, Rohner A, Pretorius J, Kostenuik P, Feige U, Zack D. The evolving systemic and local biomarker milieu at different stages of disease progression in rat adjuvant-induced arthritis. <i>J. Clin. Immunol.<\/i>, <b>29<\/b>, 158\u2013174 (2009).","DOI":"10.1007\/s10875-008-9238-8"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Wei ZF, Jiao XL, Wang T, Lu Q, Xia YF, Wang ZT, Guo QL, Chou GX, Dai Y. Norisoboldine alleviates joint destruction in rats with adjuvant-induced arthritis by reducing RANKL, IL-6, PGE<sub>2<\/sub>, and MMP-13 expression. <i>Acta Pharmacol. Sin.<\/i>, <b>34<\/b>, 403\u2013413 (2013).","DOI":"10.1038\/aps.2012.187"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Azouz AA, Saleh E, Abo-Saif AA. Aliskiren, tadalafil, and cinnamaldehyde alleviate joint destruction biomarkers; MMP-3 and RANKL; in complete Freund\u2019s adjuvant arthritis model: downregulation of IL-6\/JAK2\/STAT3 signaling pathway. <i>Saudi Pharm. J.<\/i>, <b>28<\/b>, 1101\u20131111 (2020).","DOI":"10.1016\/j.jsps.2020.07.011"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Chuang KC, Lai YW, Ko CH, Yen CC, Chen HL, Lan YW, Chen CF, Chen W, Chen CM. Therapeutic effects of kefir peptides on adjuvant-induced arthritis in rats through anti-inflammation and downregulation of matrix metalloproteinases. <i>Life Sci.<\/i>, <b>317<\/b>, 121411 (2023).","DOI":"10.1016\/j.lfs.2023.121411"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Chen DY, Chen YM, Chen HH, Hsieh CW, Lin CC, Lan JL. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-\u03b1 therapy. <i>Arthritis Res. Ther.<\/i>, <b>13<\/b>, R126 (2011).","DOI":"10.1186\/ar3431"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Alzabin S, Abraham SM, Taher TE, Palfreeman A, Hull D, McNamee K, Jawad A, Pathan E, Kinderlerer A, Taylor PC, Williams R, Mageed R. Incomplete response of inflammatory arthritis to TNF\u03b1 blockade is associated with the Th17 pathway. <i>Ann. Rheum. Dis.<\/i>, <b>71<\/b>, 1741\u20131748 (2012).","DOI":"10.1136\/annrheumdis-2011-201024"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Liu Z, Song L, Wang Y, Xu P, Guo X, Yang J, Liu H, Wang Y, Wu C, Zhang T, Yu D, Opoku YK, Khoso MH, Ren G, Li D. A novel fusion protein attenuates collagen-induced arthritis by targeting interleukin 17A and tumor necrosis factor \u03b1. <i>Int. J. Pharm.<\/i>, <b>547<\/b>, 72\u201382 (2018).","DOI":"10.1016\/j.ijpharm.2018.05.058"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/7\/48_b25-00249\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:04:56Z","timestamp":1754107496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/7\/48_b25-00249\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":33,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00249","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"type":"print","value":"0918-6158"},{"type":"electronic","value":"1347-5215"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"article-number":"b25-00249"}}